Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...

(Bloomberg) -- Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest ...

Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn ...

In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. PFE has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a Delaware ...

, opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.

(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...

(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...

Die Pfizer-Anleihe ist handelbar unter der WKN A2RY25 bzw. der ISIN US717081EV18. Die Anleihe wurde am 11.03.2019 emittiert und hat eine Laufzeit bis 15.03.2049. Das Emissionsvolumen betrug bis zu ...